Skip to Content

Research

Explore Boise VA’s nationally recognized research initiatives, with specialty research in infectious diseases, wound healing, oncology, respiratory disease, and PTSD.

About Us

Boise VA Medical Center hosts an active research program with 25 investigators conducting over 40 research projects and clinical trials. The research program has funding from NIH, VA, foundations and industry, and has collaborative affiliations with University of Washington, Boise State University, and Idaho State University.

Contact Us

Boise VA Medical Center Research Office

Why VA Research Matters

Research studies are important, because they can help provide:

  • An organized, methodical way to learn more about a specific concern
  • Answers about whether or not a treatment is effective
  • A better understanding about which health care services are effective and efficient
  • Opportunities to test whether a drug or piece of equipment is safe and effective
  • Answers to questions about the best way to treat or prevent an illness

If you decide to volunteer for a research study, you can change your mind at any time. Your decision to participate will not affect your VA benefits.

Current Research

Current and ongoing clinical and basic science research includes projects in the following areas:

  • Infectious Diseases
  • Antibiotic Stewardship
  • Microbiome
  • Oncology
  • Gene Therapy
  • Diabetic Wounds
  • PTSD
  • Depression
  • OCD
  • COPD

Public Information

Institutional Biosafety Committee:

The Boise VA Medical Center’s Institutional Biosafety Committee (IBC) oversees research involving: (i) recombinant nucleic acid molecules, (ii) synthetic nucleic acid molecules, and (iii) cells, organisms, and viruses containing such molecules. Comprised of subject matter experts and community members, the IBC conducts risk assessments to ensure a high standard of biosafety and containment to protect research staff, the public, and the environment. The Boise VA IBC complies with NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules (April 2024), maintains registration with the NIH Office of Science Policy (OSP), and will publicly share meeting minutes.